Currently, there are 507.63M common shares owned by the public and among those 506.32M shares have been available to trade.
The company’s stock has a 5-day price change of 0.57% and 8.38% over the past three months. BAX shares are trading -3.98% year to date (YTD), with the 12-month market performance up to 1.37% higher. It has a 12-month low price of $31.01 and touched a high of $44.01 over the same period. BAX has an average intraday trading volume of 4.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.85%, -0.90%, and -2.35% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Baxter International Inc. (NYSE: BAX) shares accounts for 91.22% of the company’s 507.63M shares outstanding.
It has a market capitalization of $18.94B and a beta (3y monthly) value of 0.60. The earnings-per-share (ttm) stands at -$0.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.23% over the week and 2.37% over the month.
Earnings per share for the fiscal year are expected to increase by 13.34%, and 2.42% over the next financial year.
Looking at the support for the BAX, a number of firms have released research notes about the stock. Morgan Stanley stated their Underweight rating for the stock in a research note on July 15, 2024, with the firm’s price target at $39-$30. Goldman coverage for the Baxter International Inc. (BAX) stock in a research note released on May 30, 2024 offered a Neutral rating with a price target of $36. TD Cowen was of a view on May 10, 2024 that the stock is Hold, while Morgan Stanley gave the stock Equal-Weight rating on May 30, 2023, issuing a price target of $45. UBS on their part issued Neutral rating on March 29, 2023.
